Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesTransplanttdsfidelis progenitor cell coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedtdsfidelisPolicy MC.CP.MP.249

    Allogeneic Hematopoietic Progenitor Cell Therapy

    Customize your policy alerts

    Sign up for tdsfidelis Policy MC.CP.MP.249 alerts

    Get alerted when Policy MC.CP.MP.249 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Establishes medical-necessity criteria for Omisirge (omidubicel) and RegeneCyte (HPC Cord Blood) for Medicare Advantage members when applicable Medicare coverage criteria are unavailable.

    Policy Summary
    Payertdsfidelis
    PolicyAllogeneic Hematopoietic Progenitor Cell Therapy
    Policy CodePolicy MC.CP.MP.249
    Change TypeModified
    Effective DateN/A
    Last ReviewApr 1, 2026
    Next Review DateN/A
    Key ActionReview applicable Medicare NCDs, LCDs, and Medicare Coverage Articles before applying the policy criteria.
    SourceLink
    POLICY UPDATE CHANGES

    RegeneCyte was added as a covered medically necessary allogeneic hematopoietic progenitor cell therapy with criteria for unrelated-donor transplantation.

    Omisirge coverage was expanded to include members six years of age and older with severe aplastic anemia following reduced-intensity conditioning.

    The policy description and background were updated to incorporate evidence and criteria for severe aplastic anemia treated with Omisirge.

    2Therapies addressed
    12+ yearsMinimum age for Omisirge in malignancies
    6+ yearsMinimum age for Omisirge in aplastic anemia

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1Required Omisirge administration
    87%Neutrophil recovery in cited study
    324Patients in cited RegeneCyte study

    Product-Specific Coverage Criteria

    Omisirge (omidubicel)

    Omisirge is medically necessary when either the hematologic malignancy criteria or the severe aplastic anemia criteria are met.

    Omisirge indications

    • Hematologic malignancies

      • Age: Member/enrollee is at least 12 years of age.≥ 12 years
      • Transplant plan: Member/enrollee is planned for an umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection.
      • Administration: The request is for one administration after myeloablative conditioning.one administration
    • Severe aplastic anemia

      • Age: Member/enrollee is at least six years of age.≥ 6 years
      • Administration and conditioning: The request is for one administration following reduced-intensity conditioning.one administration

    RegeneCyte HPC Cord Blood

    RegeneCyte is medically necessary when all of the following criteria are met.

    RegeneCyte criteria

    • Donor and transplant procedure: Member/enrollee is planned for an unrelated donor hematopoietic progenitor cell transplantation procedure.unrelated donor
    • Preparative regimen: An appropriate preparative regimen for hematopoietic and immunologic reconstitution will be used in conjunction with the transplantation procedure.
    • Underlying disorder: Member/enrollee has a disorder affecting the hematopoietic system that is inherited, acquired, or a result of myeloablative treatment.

    Allogeneic Hematopoietic Progenitor Cell Therapy Candidates

    Allogeneic hematopoietic progenitor cell therapy candidates

    Candidate must satisfy the applicable product-specific transplant criteria.

    Covered transplant candidates

    • Omisirge candidate: Candidate has hematologic malignancy with age at least 12 years and planned umbilical cord blood transplantation after myeloablative conditioning, or severe aplastic anemia with age at least six years and planned administration after reduced-intensity conditioning.
    • RegeneCyte candidate: Candidate is planned for unrelated donor hematopoietic progenitor cell transplantation with an appropriate preparative regimen and has an inherited, acquired, or treatment-related hematopoietic-system disorder.

    Applicable HCPCS Codes

    HCPCS CodesHCPCS
    J3590Unclassified biologics
    C9399Unclassified drugs or biologicals

    Coverage Review and Documentation Guidance

    Note

    Review Applicable Medicare Coverage Criteria

    Before applying the criteria in this clinical policy for a Medicare member, review all applicable Medicare coverage requirements to ensure consistency with current Medicare guidance.

    • Review applicable Medicare National Coverage Determinations (NCDs).
    • Review applicable Medicare Local Coverage Determinations (LCDs).
    • Review applicable Medicare Coverage Articles.
    • Refer to the CMS website for additional Medicare coverage information.
    Documentation Required

    Review Governing Coverage Documents and Guidance

    Use this clinical policy only as a medical-necessity guide. Coverage and payment remain subject to the member's governing coverage documents and all applicable legal, regulatory, and administrative requirements.

    • Review the applicable evidence of coverage, certificate of coverage, policy, insurance contract, and other coverage documents.

    Clinical Background

    Allogeneic hematopoietic cell transplantation uses stem cells collected from a related or unrelated healthy donor rather than from the patient. Before the transplant, the patient receives conditioning therapy—high-dose chemotherapy, with or without radiation therapy—to eradicate disease and prepare the bone marrow for rescue. The donor stem cells are then infused to restore bone marrow and normal immune function. This treatment is used for cancer and diseases of the blood system; the policy addresses cord-blood-derived therapies used to support hematopoietic recovery and reduce infection risk in appropriate transplant settings.

    Policy Definitions

    Myeloablative conditioning
    RegimenA single agent or combination of agents anticipated to destroy hematopoietic cells in the bone marrow.
    Target cellsThe stem cells in the bone marrow that produce new blood cells.
    Hematologic effectExtensive pancytopenia occurs within one to three weeks after administration and is typically irreversible.
    Conditioning
    TreatmentHigh-dose chemotherapy used during the conditioning phase, with or without radiation therapy.
    PurposeTo eradicate the disease before stem-cell infusion.
    Following infusion
    Policy Summary
    Payertdsfidelis
    PolicyAllogeneic Hematopoietic Progenitor Cell Therapy
    Policy CodePolicy MC.CP.MP.249
    Change TypeModified
    Effective DateN/A
    Last ReviewApr 1, 2026
    Next Review DateN/A
    Key ActionReview applicable Medicare NCDs, LCDs, and Medicare Coverage Articles before applying the policy criteria.
    SourceLink
    On This Page
    Product-Specific Coverage CriteriaAllogeneic Hematopoietic Progenitor Cell Therapy CandidatesApplicable HCPCS CodesCoverage Review and Documentation GuidanceClinical BackgroundPolicy Definitions
  1. Apply all applicable exclusions, limitations, terms, and conditions, including Health Plan-level administrative policies and procedures.
  2. This policy is not a contract or guarantee of payment or results.
  3. For Medicaid members, state Medicaid coverage provisions take precedence when they conflict with this policy.
  4. If the policy effective date conflicts with an applicable legal or regulatory requirement, the law or regulation governs.
  5. Denial Risk

    Product-Specific Criteria Must Be Met

    A requested therapy may be denied as not medically necessary when it does not satisfy the applicable product-specific criteria in this policy, even when the therapy is otherwise clinically appropriate.

    • For Omisirge (omidubicel), verify the applicable diagnosis-specific requirements, age threshold, transplant or conditioning plan, and single-administration limitation.
    • For RegeneCyte, verify the unrelated-donor hematopoietic progenitor cell transplantation, appropriate preparative regimen, and qualifying hematopoietic-system disorder.
    • Document how the requested product and indication meet every applicable criterion before submitting the request or claim.
    Infused stem cells rescue the bone marrow and restore normal immune function.
    Allogeneic hematopoietic cell transplantation
    DefinitionHematopoietic cell transplantation using stem cells collected from a healthy donor rather than from the patient.
    Donor relationshipThe donor may be related or unrelated to the patient.
    Treatment sequenceStem-cell infusion follows conditioning therapy to rescue the bone marrow and restore normal immune function.
    Health Plan
    DefinitionA health plan that has adopted this clinical policy.
    AdministrationThe health plan is operated or administered, in whole or in part, by Centene Management Company, LLC or one of its applicable affiliates.
    Policy roleThe clinical policy provides guidance to medical necessity and assists in making coverage decisions and administering benefits.